InvestSMART

Recce Pharmaceuticals Ltd (ASX:RCE)

ALERT: Price-sensitive ASX Announcement for RCE
Current share price for RCE : $0.370 -0.035 (-8.64%)+
Announcement
Release
1 Jul 2026 9:07AM
Price at Release
$0.405
Full Release
download
Summary
Recce Pharmaceuticals Ltd announced the receipt of an AUD $3.7 million income tax refund from the Australian Taxation Office for the financial year ending 30 June 2025. This refund is primarily due to the company's overseas R&D expenditure. The company anticipates further non-dilutive funding and has plans to raise additional capital to support its clinical trial milestones. The announcement highlights Recce's efforts in developing synthetic anti-infectives to combat antibiotic-resistant superbugs.
Key Points
  • Recce Pharmaceuticals received an AUD $3.7 million income tax refund.
  • The refund is for overseas R&D expenditure for FY2025.
  • The company plans to raise further capital to support clinical trials.
  • Recce is focused on developing synthetic anti-infectives for antibiotic resistance.
  • The company expects an additional R&D Tax Incentive rebate in FY2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.